Race to Yes Underscores Evidence Presented at FDA Advisory Committee Meeting for Duchenne Muscular Dystrophy Drug Eteplirsen Organization Urges FDA to Use the Evidence Presented by Dozens of Scientists, Physicians, Patients and Advocates as Required by 2012 FDASIA Act for Conditional Approval Experts Remind Duchenne...

Race to Yes Calls on FDA Advisory Committee: Carefully Consider Data and Recommend Duchenne Drug Approval Based on Data and Direct Experience of Children and Clinicians WASHINGTON, April 22, 2016 (GLOBE NEWSWIRE) -- In what is predicted to be the largest turnout in history at an FDA Advisory Committee meeting, more than 800 clinicians, researchers, patients and...